Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | PAR 21 329

Opportunity Information: Apply for PAR 21 329

The National Institutes of Health (NIH) funding opportunity PAR-21-329, titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)," supports research aimed at understanding and ultimately reducing the long-term health problems that can follow cancer treatment. The central focus is on adverse sequelae from cancer therapies that either persist after treatment and turn into chronic comorbidities (ongoing conditions that affect quality of life and health) or appear later as delayed post-treatment effects. In practical terms, the FOA is targeting the kinds of lasting or late-emerging complications that cancer survivors may experience, with an emphasis on generating evidence that can lead to prevention or mitigation strategies rather than only describing the problem.

This FOA is designed for collaborative projects and welcomes a broad range of study types across the basic-to-clinical spectrum. It explicitly supports basic research, translational research, and clinical research, as long as the work is clearly tied to therapy-induced adverse sequelae. Projects may concentrate on one or more of three major aims: first, identifying biological or physiological mechanisms that drive therapy-related adverse sequelae; second, clinically characterizing these sequelae in patients, including how they present, progress, and vary across individuals; and third, using mechanistic insights to develop or refine therapeutic approaches that prevent these sequelae from developing or reduce their severity. The "clinical trial optional" designation indicates that applicants may propose clinical trials if appropriate, but they are not required to do so to be responsive.

A key expectation in this program is that studies will not stop at identifying associations. The FOA emphasizes mechanistic studies with translational endpoints and encourages longitudinal clinical phenotyping, meaning repeated, systematic assessments of patients over time. The purpose of that longitudinal approach is to capture how adverse effects evolve from treatment through survivorship and to identify measurable indicators that can serve as dependable endpoints for future interventional trials. The endpoints the FOA highlights include biomarkers, imaging measures, patient-reported outcomes, or combinations of these elements. In other words, the program is looking for projects that can help define what should be measured in later trials that test interventions, how to measure it consistently, and how to validate that those measures truly reflect the adverse sequela being targeted.

The overall logic of the FOA is to build a pipeline from mechanism to measurement to intervention. By supporting research that clarifies underlying causes and simultaneously develops clinically meaningful endpoints, NIH is aiming to accelerate the design of future trials that evaluate interventions intended to prevent or reduce specific long-term toxicities of cancer therapy. Projects that integrate mechanistic understanding with real-world clinical characterization, and that produce validated outcome measures suitable for broader trial use, are especially aligned with the announcement's stated goals.

The award mechanism is an R01 grant, and the opportunity is categorized as a discretionary grant program in the education and health area, with CFDA number 93.393. The listed agency is the National Institutes of Health. The opportunity was created on 2021-09-22, and the original closing date provided is 2024-11-05. An award ceiling is not specified in the provided source details, and the expected number of awards is also not provided in the excerpt.

Eligibility is broad and includes many types of U.S. applicants as well as certain non-U.S. organizations. Eligible applicants include state, county, city or township governments, special district governments, and independent school districts; public and state-controlled institutions of higher education as well as private institutions of higher education; federally recognized Native American tribal governments and other Native American tribal organizations; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other categories. The FOA also calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and non-domestic (non-U.S.) entities (foreign organizations). This wide eligibility list signals an intent to encourage participation from diverse institutional settings, including community-based groups and minority-serving institutions, and to allow international partners where scientifically justified.

In summary, PAR-21-329 is aimed at advancing survivorship science by funding research that explains why cancer therapies cause certain long-term or delayed adverse effects, carefully documents how those effects develop over time in patients, and turns that knowledge into practical strategies and validated endpoints that can support future intervention trials. The program is positioned to help move the field from recognizing chronic treatment-related problems to building measurable, mechanism-based solutions that can be tested and implemented to improve long-term outcomes for people treated for cancer.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393.
• This funding opportunity was created on 2021-09-22.
• Applicants must submit their applications by 2024-11-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 21 329

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: